TP53 and ovarian carcinoma: Furthermore, analyses using the TCGA ovarian cancer RNA-seq dataset presented via the UCSC Xena platform [31] for PFS in platinum drug-sensitive or -resistant groups with TP53 null or -missense mutations displaying a high level of ABCB1 expression revealed that patients sensitive to platinum drugs showed significantly longer PFS than those who were platinum drug-resistant.